Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.
Euroasian J Hepatogastroenterol
December 2024
Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Unlabelled: The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments.
View Article and Find Full Text PDFInduction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation.
JHEP Rep
January 2025
Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background & Aims: Hepatic steatosis, characterized by lipid accumulation in hepatocytes, is a key diagnostic feature in patients with chronic hepatitis C virus (HCV) infection. This study aimed to clarify the involvement of phospholipid metabolic pathways in the pathogenesis of HCV-induced steatosis.
Methods: The expression and distribution of lipid species in the livers of human liver chimeric mice were analyzed using imaging mass spectrometry.
Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy.
Int J Nanomedicine
January 2025
College of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, Zhejiang, People's Republic of China.
Background: Cancer immunotherapy has achieved great success in breast cancer treatment in recent years. The Programmed Death-1 (PD-1) /Programmed Death-Ligand 1 (PD-L1) immune checkpoint pathway is among the most studied. BMS-1166, a PD-L1 inhibitor, can interfere with PD-1 and PD-L1 interaction.
View Article and Find Full Text PDFA Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model.
Int J Nanomedicine
January 2025
Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing, People's Republic of China.
Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity.
Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease.
Mitochondria-Targeting Type-I Photodynamic Therapy Based on Phenothiazine for Realizing Enhanced Immunogenic Cancer Cell Death via Mitochondrial Oxidative Stress.
Int J Nanomedicine
January 2025
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People's Republic of China.
Purpose: Photo-immunotherapy faces challenges from poor immunogenicity and low response rate due to hypoxic microenvironment. This study presents Rh-PTZ, a small organic molecule with a D-π-A structure, that simultaneously amplifies mitochondria-targeted type-I PDT-dependent immune stimulation for the treatment of hypoxic cancer.
Methods: The hydrophobic Rh-PTZ was encapsulated into F127 to prepare Rh-PTZ nanoparticles (Rh-PTZ NPs).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!